Novo Nordisk | NVO - Ebitda

Stock Price
50.30
Daily Change
-8.71 -14.76%
Monthly
-8.81%
Yearly
-39.15%
Q1 Forecast
56.42

Novo Nordisk reported DKK31.44B in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
ANI Pharmaceuticals USD 59.6M 5.52M Sep/2025
Aurora Cannabis CAD 15.37M 26.8M Sep/2025
Bausch Health Companies USD 986M 74M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Canopy Growth CAD 16.62M 38.45M Sep/2025
Corcept Therapeutics USD 27.14M 23.27M Jun/2025
Drreddys Laboratories INR 21.59B 1.49B Dec/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
GlaxoSmithKline GBP 3.18B 45M Jun/2025
Merck USD 8.39B 1.97B Sep/2025
Novartis USD 5.88B 290M Sep/2025
Novo Nordisk DKK 31.44B 6.84B Sep/2025
Novo Nordisk DKK 31.44B 6.84B Sep/2025
Pacira USD 49.36M 4.96M Sep/2025
Perrigo USD 258.8M 37.3M Sep/2025
Prestige Brands USD 86.83M 7.19M Sep/2025
Sanofi EUR 4.84B 2.95B Sep/2025
Supernus Pharmaceuticals USD 41.9M 432K Sep/2025
Zoetis USD 1.04B 87M Sep/2025